BIOMAPS

BIOMAPS is a CNRS – Gustave Roussy – University of Paris-South Mixed Research Unit

This research unit is located on three sites:

Physiology and Molecular Pathology of Endogenous and Infectious Retroviruses

This Research Unit is composed of the "Physiology and Molecular Pathology of Endogenous and Infectious Retroviruses" team.

The Unit's work, historically focused on retroelements and retroviruses, has made significant contributions to:

Lab members

• Fathia Mami-Chouaib (DR1 INSERM): group leader
• Pascale Leroy (CRCN, CNRS)
• Julien Adam (PH, IGR)
• Stéphanie Corgnac (Post-Doc, IGR)
• Marine Leclerc (Post-Doc, IGR)
• Inès Malenica (Post-Doc, INSERM)
• Isabelle Tihy (PhD student, Paris XI)
• Gwendoline Gros (AI, INSERM)
• Jamila Kacher (IE, CDD, INSERM)
• Laetitia Grynszpan (TCN, CDD, IGR)
• Vincent de Montpreville (PH, Centre Chirurgical Marie Lannelongue)
• Clara Coelho Basto (M2, Paris XI)

Major publications

1. DJENIDI F, ADAM J, GOUBAR A, DURGEAU A, MEURICE G, DE MONTPREVILLE V, VALIDIRE P, BESSE B and MAMI-CHOUAIB F. CD8⁺/CD103⁺ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015 Apr 1;194(7):3475-86.

Researchers

Dr. Michele MONDINI (CRCN, INSERM)
Dr. Charlotte ROBERT (MCU, Paris Saclay, Gustave Roussy)

Doctors/Pharmacists/Physicists

Major Publications

• Meziani L, Gerbé de Thoré M, Hamon P, Bockel S, Andrade Louzada A, Clemenson C, Corré E, Liu W , Dupuy C, Mondini M, Deutsch E. “Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages” J Immunother Cancer 2020

ImmunoRadAI

This group belongs to the UMR 1030 Molecular Radiotherapy and Novel Therapeutics

Lab members

Group manager : Pr. Laurence ZITVOGEL (PU-PH Kremlin Bicêtre)

• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Tumour immunology and immunotherapy

Group 1 of the Inserm (National Institute of Health and Medical Research) UMR 1015 research unit, « Tumour immunology and immunotherapy of cancer », is under the direction of Professor Laurence Zitvogel.  Between 2015 and 2018 it will be exploring three lines of research: 
-    Gut microbiota and pro- or anti-tumour inflammatory/immunological activity, by measuring the effect of specific therapies on their regulation,